Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Running, not enrolling · Phase 1
Conditions studied: Healthy Participants
In brief
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Key facts
- Study ID
- NCT06916143
- Run by
- Eli Lilly and Company
- People needed
- 48
- Starts
- 2025-04-08
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Body mass index between 18.0 and 32.0 kilograms per meter squared (kg/m2), inclusive, and a body weight of ≥50 kg.
- In good health, as determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG) and vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the Investigator (or designee).
You may not qualify if…
- Have a 12-lead ECG abnormality that, in the opinion of the Investigator,
- increases the risk associated with participating in the study
- may confound ECG data analysis
- a QTcF: >450 millisecond (msec) for males, or >470 msec for females
- short PR interval <120 msec or PR interval >220 msec
- second or third degree atrioventricular block
- intraventricular conduction delay with QRS >120 msec
- complete right bundle branch block
- left bundle branch block, or
- Wolff Parkinson-White syndrome
- Have a current or recent acute, active infection (for example, for a least 30 days before screening and up to Day -1, participants must have no symptoms or signs of infection in the absence of any anti-infective treatment).
- Had any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or metastatic disease within the 3 years prior to baseline.
- Have inflammatory bowel disease (IBD), including ulcerative colitis or Crohn's disease.
Where it is running
- Clinical Pharmacology of Miami — Miami, Florida, United States
- Alliance for Multispecialty Research, LLC — Knoxville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.